Perspectives
Feb 20, 2025
Maha Radhakrishnan Shares Insights with NYSE “We’re Cure(ious) About the Future of Healthcare” Series
link
Perspectives
Feb 14, 2025
Maha Radhakrishnan Featured in BioSpace: The Rise of China Innovation in the Time of Trump
link
Perspectives
Feb 14, 2025
Jakob Dupont Highlighted in “Key takeaways from the JP Morgan Healthcare Conference”
link
Portfolio News
Apr 2, 2025
Atsena Announced Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs
link
Sofinnova News
Aug 6, 2024
Sofinnova Investments Announces the Addition of Dr. Maha Radhakrishnan as Executive Partner
link
Sofinnova News
Mar 12, 2024
Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor
link
Portfolio News
May 20, 2025
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
link
Portfolio News
May 20, 2025
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
link
Portfolio News
May 20, 2025
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
link
Event
May 20, 2025
Maha Radhakrishnan to Speak at “The Investment Heat Map: Where Capital’s Surging—and Where It’s Not” at CHPI Americas on May 20th at 10:25 ET
link
Event
Apr 24, 2025
Maha Radhakrishnan To Join Keynote Sessions During LSX World Congress Europe on April 29th at 11:10AM BST & April 30th at 9:05AM BST
link
Event
Mar 27, 2025
Jakob Dupont to Join Fireside Chat: Riding the Next Biotech Wave—Trends in Biotech Investments, Partnering, and M&As During PEGS on May 15th at 11:35AM ET
link
Event
May 20, 2025
Maha Radhakrishnan to Speak at “The Investment Heat Map: Where Capital’s Surging—and Where It’s Not” at CHPI Americas on May 20th at 10:25 ET
link
Portfolio News
May 20, 2025
NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology
link
Portfolio News
May 20, 2025
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
link
Portfolio News
May 20, 2025
Atsena Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
link
Portfolio News
May 20, 2025
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
link
Portfolio News
May 20, 2025
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
link
Portfolio News
May 20, 2025
Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
link
Portfolio News
May 20, 2025
Aeovian Pharmaceuticals Doses First Participants in Phase 1 Clinical Trial, Strengthens Leadership Team and Raises Additional $50 Million Financing
link
Portfolio News
May 7, 2025
Marea Presented Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
link
Event
Apr 24, 2025
Maha Radhakrishnan To Join Keynote Sessions During LSX World Congress Europe on April 29th at 11:10AM BST & April 30th at 9:05AM BST
link
Portfolio News
Apr 15, 2025
Atsena Granted U.S. FDA Regenerative Medicine Advanced Therapy Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
link
Portfolio News
Apr 2, 2025
Atsena Announced Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs
link
Event
Apr 1, 2025
Maha Radhakrishnan to Join “The Investment Heat Map: Where Capital’s Surging—and Where It’s Not” Panel During CPHI Americas on May 20th at 10:25AM ET
link
Event
Mar 27, 2025
Maha Radhakrishnan To Join “Weight Loss for Longevity? How Metabolic Drugs are Disrupting Chronic Disease and Improving Healthspan” Panel During BIO on June 18th at 9AM ET
link
Event
Mar 27, 2025
Maha Radhakrishnan to Join “Next-Generation Alzheimer’s Disease Therapies” Panel During BIO Panels during BIO 2025 on June 16th at 4:15PM ET
link
Event
Mar 27, 2025
Jakob Dupont to Join Fireside Chat: Riding the Next Biotech Wave—Trends in Biotech Investments, Partnering, and M&As During PEGS on May 15th at 11:35AM ET
link
Portfolio News
Mar 21, 2025
VISEN Pharmaceuticals Announced the Offer Price and Allotment Results of the Global Offering
link
Portfolio News
Feb 28, 2025
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
link
Portfolio News
Feb 28, 2025
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
link
Event
Feb 20, 2025
Jakob Dupont to Join “What Investors Are Looking For in 2025” panel during Chief Medical Officer Summit 360 on April 8th at 10:35am ET
link
Event
Feb 20, 2025
Maha Radhakrishnan to Join “Capital Currents: Navigating the Waves of Healthcare Investment in 2025” at Investival Showcase on March 10 at 9am ET
link
Perspectives
Feb 20, 2025
Maha Radhakrishnan Shares Insights with NYSE “We’re Cure(ious) About the Future of Healthcare” Series
link
Perspectives
Feb 14, 2025
Maha Radhakrishnan Featured in BioSpace: The Rise of China Innovation in the Time of Trump
link
Perspectives
Feb 14, 2025
Jakob Dupont Highlighted in “Key takeaways from the JP Morgan Healthcare Conference”
link
Perspectives
Feb 14, 2025
Maha Katabi Featured in JPM25: Oncology Outlook for 2025
link
Perspectives
Feb 13, 2025
Maha Katabi Featured in “‘A really rational IPO environment’: What does it takes for a biotech to go public now?”
link
Portfolio News
Feb 12, 2025
OnCusp Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
link
Event
Feb 11, 2025
Maha Katabi to Speak at STAT Breakthrough SUMMIT EAST on March 20th
link
Event
Feb 7, 2025
Maha Radhakrishnan, to join “From Clinical Trials to Commercialization: Matching Strategy to Size of Patient Population” panel during the BIO CEO & Investor Conference on Monday, February 10 at 2pm ET
link
Portfolio News
Jan 13, 2025
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
link
Event
Jan 13, 2025
Maha Katabi to join “Priorities in Oncology R&D” panel during Endpoints at JPM25 on January 14 at 10:30am PT
link
Event
Jan 13, 2025
Maha Radhakrishnan to join “Alzheimer’s & Other Neurodegenerative Diseases” panel during Biotech Showcase on Janaury 14 at 8am PT
link
Event
Jan 13, 2025
Jim Healy to join “Financing the Biotech Sector” panel during Biotech Showcase on January 15 at 12pm PT
link
Portfolio News
Jan 10, 2025
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
link
Portfolio News
Jan 9, 2025
Rapport Therapeutics Announces New Phase 1 Data, Supporting RAP-219’s Transformative Potential for CNS Disorders
link
Portfolio News
Jan 9, 2025
Marea Announces Topline Results from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
link
Portfolio News
Jan 8, 2025
Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
link
Portfolio News
Jan 7, 2025
Exclusive: Avenzo picks up another ADC, this time with multi-partnered DualityBio
link
Portfolio News
Jan 6, 2025
Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)
link
Portfolio News
Dec 18, 2024
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
link
Portfolio News
Nov 18, 2024
Alkeus Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease
link
Event
Oct 31, 2024
Maha Radhakrishnan presents Keynote Address: “The Case For Transforming Neurology From China” and joins Biotech CEO Roundtable during Bio Century Healthcare Summit on October 31, 2024
link
Portfolio News
Oct 30, 2024
Axonis Announces $115M Series A Financing
link
Portfolio News
Oct 29, 2024
Vera Announces Pricing of Public Offering of Class A Common Stock
link
Portfolio News
Oct 26, 2024
Vera Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN
link
Portfolio News
Oct 21, 2024
Seaport Closes $225M Oversubscribed Series B Financing Round
link
Portfolio News
Oct 2, 2024
Vera Announced Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
link
Portfolio News
Sep 30, 2024
Ascendis Presented New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) at ASBMR 2024
link
Perspectives
Sep 26, 2024
Jim Healy Featured in WSJ: “Venture Mega-Rounds Return to Biotech”
link
Portfolio News
Sep 26, 2024
BioAge Labs Announces Pricing of Upsized Initial Public Offering
link
Portfolio News
Sep 16, 2024
Ascendis Announced Topline Data From ApproaCH Trial of TransCon CNP
link
Perspectives
Sep 13, 2024
Jim Healy Speaks with Endpoints News on ‘More Rational Market’ as Four Biotech Startups Near their IPOs
link
Portfolio News
Sep 9, 2024
ArriVent Announced Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer
link
Portfolio News
Aug 12, 2024
Ascendis Announced FDA has Approved YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults
link
Sofinnova News
Aug 6, 2024
Sofinnova Investments Announces the Addition of Dr. Maha Radhakrishnan as Executive Partner
link
Portfolio News
Jul 29, 2024
BioAge Announces First Patient Dosed in the STRIDES Phase 2 Clinical Trial Evaluating Azelaprag as a Novel Treatment for Obesity in Combination with Tirzepatide
link
Portfolio News
Jun 27, 2024
Quanta Announces Dosing of First Patient in Phase 1/1b Clinical Trial of QTX3046 and Other Program Updates
link
Portfolio News
Jun 21, 2024
BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs
link
Portfolio News
Jun 18, 2024
Marea Launches with $190M to Accelerate a New Generation of Medicines for Cardiometabolic Diseases
link
Portfolio News
Jun 7, 2024
Rapport Announces Pricing of Initial Public Offering
link
Portfolio News
Jun 5, 2024
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
link
Portfolio News
May 28, 2024
Vera Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
link
Portfolio News
May 13, 2024
Ascendis Reports Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH
link
Portfolio News
May 8, 2024
Alkeus Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
link
Event
May 1, 2024
Jakob Dupont to join “The Latest Trends in Venture Capital Investing” panel during LABEST on May 23 at 3:00pm PT
link
Event
Apr 18, 2024
Jakob Dupont To Join “What Investors Are Looking For in 2024” panel during CMO360 Summit
link
Portfolio News
Apr 9, 2024
Seaport Launches with $100M Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines
link
Portfolio News
Apr 8, 2024
Inozyme Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
link
Event
Mar 28, 2024
Jakob Dupont to join “AI’s Impact on Oncology Cancer Drug Development” panel during BIO 2024 on June 5 at 3:00pm PT
link
Perspectives
Mar 27, 2024
Maha Katabi Featured in NVCA Member Spotlight
link
Portfolio News
Mar 26, 2024
Avenzo Therapeutics Announces $150M Oversubscribed Financing To Advance Emerging Oncology Pipeline
link
Portfolio News
Mar 20, 2024
Capstan Therapeutics Announces $175M Oversubscribed Series B Financing
link
Sofinnova News
Mar 12, 2024
Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor
link
Sofinnova News
Feb 16, 2024
Maha Katabi Speaks with Endpoints News on Recent M&A, IPO, and Deal Flow Activity
link
Portfolio News
Feb 13, 2024
BioAge Announces $170M Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
link
Event
Feb 3, 2024
Maha Katabi to join “IPO Insights” panel at Evercore ISI 2024 Emerging Biotech Conference on February 28th at 12pm ET
link
Portfolio News
Feb 1, 2024
Vera Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
link
Portfolio News
Jan 30, 2024
Vera Announces Pricing of Upsized Public Offering of Class A Common Stock
link
Portfolio News
Jan 25, 2024
ArriVent Announces Pricing of Upsized Initial Public Offering
link
Portfolio News
Jan 25, 2024
Vera Announced Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
link
Sofinnova News
Jan 11, 2024
Jim Healy Shares Perspective on What’s Driving M&A Optimism for 2024 with WSJ
link
Portfolio News
Jan 10, 2024
Alkeus Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression
link
Portfolio News
Jan 9, 2024
GSK Enters Agreement to Acquire Aiolos Bio
link
Portfolio News
Jan 4, 2024
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients
link
Portfolio News
Dec 26, 2023
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
link
Portfolio News
Dec 22, 2023
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
link
Portfolio News
Dec 20, 2023
Ascendis Announces Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide)
link
Portfolio News
Dec 14, 2023
Karuna Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
link
Sofinnova News
Dec 13, 2023
BioSpace Reporter Tyler Patchen Spoke with Jakob Dupont and Other Industry Professionals for Advice on How to Optimize Time at JPM Healthcare Conference
link
Portfolio News
Nov 29, 2023
Karuna Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
link
Sofinnova News
Nov 27, 2023
Maha Katabi Named One of Fierce Biotech’s 2023’s Fiercest Women in Life Sciences
link
Portfolio News
Nov 20, 2023
Aerovate Announces Simultaneous Completion of Enrollment in Phase 2b and Enrollment of First Patient into Phase 3 in IMPAHCT Trial for Pulmonary Arterial Hypertension
link
Portfolio News
Nov 16, 2023
Karuna Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
link
Portfolio News
Nov 16, 2023
Karuna Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
link
Portfolio News
Nov 14, 2023
Atsena Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy
link
Portfolio News
Nov 4, 2023
Vera Announced Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients
link
Portfolio News
Nov 3, 2023
Alkeus Presents Positive Gildeuretinol Trial Results Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
link
Portfolio News
Oct 30, 2023
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib: First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
link
Event
Oct 30, 2023
Maha Katabi to join “Revolutionizing Investment Models for Rare Disease Research” panel at Future of Health Summit on November 8th at 10:15am ET
link
Portfolio News
Oct 24, 2023
Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody
link
Portfolio News
Oct 24, 2023
FDA Selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
link
Portfolio News
Sep 28, 2023
Karuna Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
link
Portfolio News
Sep 28, 2023
Bolt Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
link
Portfolio News
Sep 15, 2023
RayzeBio Announces Pricing of Upsized $311 Million Initial Public Offering
link
Portfolio News
Sep 7, 2023
Natera Announces Pricing of $250 Million Follow-On Offering
link
Portfolio News
Sep 5, 2023
Star Therapeutics Raises $90 Million Financing to Accelerate its Pipeline of Novel Antibody Therapies
link
Event
Sep 1, 2023
Jim Healy to join “How Private Market Healthcare Investors Are Navigating Tighter Credit and Equity Markets” panel at Piper Sandler Heartland Summit on September 20th at 9am CT
link
Event
Aug 28, 2023
Regina Salvat to join “Attracting Investors And First Steps – Advice For Early Stage Biotechs” panel during LSX World Congress on September 13th at 12pm ET
link
Portfolio News
Aug 23, 2023
Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform
link
Event
Aug 20, 2023
Jakob Dupont to join “Investing in Innovation: A View from the Capital Markets” panel during Economist Impact World Cancer Series on September 21st at 3:20pm CET
link
Event
Aug 15, 2023
Jakob Dupont to join Demy-Colton Virtual Salon “VC Trends in Healthcare Investing: Current Pulse Check” on Wednesday, August 30th at 11am ET
link
Portfolio News
Aug 7, 2023
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
link
Portfolio News
Jul 26, 2023
Inozyme Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
link
Portfolio News
Jul 14, 2023
ArriVent Biopharma and InnoCare Pharma Announce Clinical Development Collaboration
link
Portfolio News
Jun 17, 2023
Vera Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
link
Portfolio News
Jun 5, 2023
Ascendis Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
link
Portfolio News
Jun 5, 2023
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
link
Portfolio News
May 31, 2023
Ascendis Oncology Program Update Highlights Latest Clinical Data for Product Candidates
link
Portfolio News
May 31, 2023
RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
link
Portfolio News
May 23, 2023
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
link
Portfolio News
May 22, 2023
Quanta Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors
link
Event
May 17, 2023
Jim Healy, Maha Katabi, and Chris Carpenter Share Their Perspective at BIO: June 5-8 in Boston
link
Sofinnova News
May 16, 2023
Sofinnova Welcomes Dr. Jakob Dupont as Executive Partner
link
Event
May 15, 2023
Maha Katabi to join panel at Yale Innovation Summit “State of the Biotech Venture Market 2023” on Thursday, June 1 at 10:00am ET
link
Portfolio News
May 1, 2023
Atsena Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis
link
Portfolio News
Apr 27, 2023
Antiva Biosciences Closes $53 Million Series E Equity Financing and Names Kristine Ball President and CEO
link
Portfolio News
Mar 29, 2023
Bolt Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
link
Portfolio News
Mar 27, 2023
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
link
Portfolio News
Mar 24, 2023
Karuna Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
link
Portfolio News
Mar 23, 2023
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement
link
Sofinnova News
Mar 22, 2023
Sofinnova Supporting Female Biotech Executives
link
Portfolio News
Mar 20, 2023
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
link
Portfolio News
Mar 20, 2023
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
link
Sofinnova News
Mar 15, 2023
Regina Salvat Featured in Biomarker: “23 Biotech VCs in ’23”
link
Portfolio News
Feb 24, 2023
Acquisition of CinCor Pharma by AstraZeneca Completed
link
Portfolio News
Feb 21, 2023
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat
link
Portfolio News
Feb 8, 2023
Atsena to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
link
Portfolio News
Jan 26, 2023
XyloCor Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina
link
Event
Jan 11, 2023
Maha Katabi to join Endpoints “Capital Markets” Panel on January 11 at 10:30am PT
link
Portfolio News
Jan 9, 2023
CinCor Pharma to be Acquired by AstraZeneca
link
Portfolio News
Jan 5, 2023
NorthSea Provides Clinical Update Reflecting Progress Across NASH and Metabolic Disorders Programmes
link
Portfolio News
Jan 4, 2023
RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)
link
Portfolio News
Jan 3, 2023
Vera Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
link
Sofinnova News
Dec 1, 2022
Maha Katabi Featured in BioWorld: “Venture Financing: Less Zoom but Still Plenty of Capital in Correcting Market”
link
Portfolio News
Dec 1, 2022
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
link
Portfolio News
Nov 28, 2022
CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension
link
Event
Nov 18, 2022
Maha Katabi to join Demy-Colton’s Virtual Salon Panel “Raising Money In This Market: Can It Be Done?” on November 30 at 11am EST
link
Portfolio News
Nov 17, 2022
Aerovate Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
link
Portfolio News
Nov 14, 2022
Ascendis Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
link
Event
Nov 8, 2022
Chris Carpenter to join “BioCentury Scene Setter Report: Does East-West Matter?” during the BioCentury Inc. BayHelix Summit on November 15 at 9am PST
link
Portfolio News
Nov 7, 2022
CinCor Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension
link
Portfolio News
Nov 5, 2022
Vera Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection
link
Portfolio News
Oct 31, 2022
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
link
Portfolio News
Oct 26, 2022
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
link
Portfolio News
Oct 18, 2022
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
link
Portfolio News
Oct 3, 2022
Y-mAbs Announces Pivotal Data for Omburtamab
link
Event
Sep 19, 2022
Maha Katabi to join “Battling Biotech’s Bear Market” Panel at the Fierce Biotech Summit on September 19th at 9:45AM ET
link
Portfolio News
Sep 13, 2022
RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer
link
Portfolio News
Sep 13, 2022
Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss
link
Portfolio News
Aug 15, 2022
CinCor Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
link
Portfolio News
Aug 12, 2022
Karuna Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
link
Portfolio News
Aug 8, 2022
Karuna Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
link
Portfolio News
Aug 8, 2022
CinCor Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension
link
Portfolio News
Aug 8, 2022
Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments
link
Portfolio News
Jul 26, 2022
CinCor Doses Last Patient in Phase 2 Study and Announce Initiation of Long-Term Extension Study for Baxdrostat in Uncontrolled Hypertension
link
Portfolio News
Jul 19, 2022
Inozyme Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency
link
Portfolio News
Jul 12, 2022
Y-mAbs’ Announces Clearance of IND for GD2-SADA
link
Portfolio News
Jul 6, 2022
Vera Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
link
Portfolio News
Jun 16, 2022
Inozyme Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases
link
Event
Jun 7, 2022
David Kabakoff to join Panel Discussion during BIO: “Next Gen Oncology Therapeutics: Changing the Cancer Landscape” on June 14 at 11:00am PT
link
Portfolio News
Jun 4, 2022
Vera Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients
link
Portfolio News
Jun 1, 2022
CinCor Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease
link
Portfolio News
May 31, 2022
Regeneron has completed its acquisition of Checkmate Pharmaceuticals
link
Portfolio News
May 26, 2022
Pionyr Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022
link
Portfolio News
May 23, 2022
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
link
Sofinnova News
Apr 5, 2022
Sofinnova Investments Announces the Addition of Dr. Chris Carpenter as Executive Partner
link
Portfolio News
Apr 4, 2022
Inozyme Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
link
Event
Mar 31, 2022
Sarah Bhagat to join Panel Discussion: “Investing in IRD Cures” at Investing in Cures Summit on April 2nd at 3:00pm PT
link
Portfolio News
Mar 28, 2022
Apellis Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
link
Portfolio News
Mar 18, 2022
CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes
link
Portfolio News
Mar 16, 2022
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
link
Sofinnova News
Mar 15, 2022
Regina Salvat Selected by Venture Forward as One of Ten Women in VC: Rising Stars to Watch
link
Portfolio News
Mar 13, 2022
Ascendis Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
link
Portfolio News
Mar 8, 2022
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314
link
Portfolio News
Mar 2, 2022
Natera and MinMinBear Foundation Announce Partnership to Provide Comfort and Support to Kidney Patients
link
Event
Feb 22, 2022
Sarah Bhagat to join Panel Discussion: Changing Lanes in Biotech Investing at Global Life Science Partnering Conference on February 23 at 12:45pm PT
link
Portfolio News
Feb 18, 2022
Gyroscope Therapeutics Acquisition is Complete
link
Portfolio News
Feb 14, 2022
Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
link
Event
Feb 3, 2022
Maha Katabi to join panel at Ontario Bioscience Innovation Organization’s Investment Summit on February 11 at 2:30PM ET
link
Portfolio News
Jan 14, 2022
Ascendis Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency
link
Portfolio News
Jan 7, 2022
CinCor Pharma Announces Pricing of Initial Public Offering
link
Portfolio News
Jan 6, 2022
Antiva Biosciences Named Winner of Global Women’s HealthTech Award by World Bank Group and Consumer Technology Association
link
Portfolio News
Dec 22, 2021
Novartis to Acquire Gyroscope Therapeutics for Up to $1.5 Billion
link
Portfolio News
Dec 17, 2021
NorthSea Therapeutics Completes $80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
link
Portfolio News
Dec 17, 2021
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
link
Portfolio News
Dec 17, 2021
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients
link
Portfolio News
Dec 15, 2021
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension
link
Portfolio News
Nov 16, 2021
NorthSea Announces Icosabutate Latest Phase 2b Interim Data Show Significant Decreases in NASH and Fibrosis Biomarkers Independent of Fibrosis Stage and Disease Severity
link
Portfolio News
Nov 8, 2021
Gyroscope Therapeutics Announces Sanofi Investment of up to $60 Million
link
Portfolio News
Nov 2, 2021
Antiva Biosciences Closes $31 Million Series D Equity Financing
link
Portfolio News
Oct 26, 2021
Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs
link
Portfolio News
Oct 12, 2021
CinCor Pharma Raises $143 Million in Series B Financing
link
Portfolio News
Oct 7, 2021
NextCure Announces Publication of Preclinical Data for NC410
link
Portfolio News
Oct 4, 2021
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program
link
Portfolio News
Sep 30, 2021
Gyroscope Therapeutics Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005
link
Event
Sep 30, 2021
Sarah Bhagat to join “Making Smart Investments” panel during Longwood Healthcare Leaders Meeting on October 4 at 5:10pm ET
link
Portfolio News
Sep 29, 2021
NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer
link
Event
Sep 23, 2021
Maha Katabi to join panel during Johnson & Johnson webinar on “Battling Chronic Kidney Disease (CKD)” on Tuesday, September 28 at 10:30am PT.
link
Portfolio News
Sep 13, 2021
Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China
link
Portfolio News
Sep 8, 2021
Bolt Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo®
link
Portfolio News
Aug 25, 2021
Ascendis Announces U.S. Food and Drug Administration Approval of SKYTROFA®, the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency
link
Portfolio News
Aug 11, 2021
Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug
link
Portfolio News
Jul 27, 2021
ObsEva and Organon Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
link
Portfolio News
Jul 27, 2021
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
link
Portfolio News
Jul 7, 2021
Neurana Pharmaceuticals Announces Publication in Pain Management
link
Portfolio News
Jul 6, 2021
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
link
Portfolio News
Jul 6, 2021
Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China
link
Portfolio News
Jul 6, 2021
Ascendis Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP)
link
Portfolio News
Jun 29, 2021
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering
link
Portfolio News
Jun 25, 2021
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA
link
Portfolio News
Jun 24, 2021
Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China
link
Portfolio News
Jun 23, 2021
Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
link
Portfolio News
Jun 22, 2021
Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids
link
Portfolio News
Jun 22, 2021
Pionyr and Abcam Extend Partnership to Evaluate TREM2-Expressing Cells in Cancer Patients
link
Event
Jun 11, 2021
Sarah Bhagat to join Panel Discussion on Neurological Disorder Therapeutics at Biotech by the Lake Summit on Tuesday, June 22 at 10:25am CST
link
Portfolio News
Jun 9, 2021
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency
link
Portfolio News
Jun 7, 2021
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study
link
Portfolio News
Jun 4, 2021
VISEN Pharmaceuticals obtained IND approval for phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathyroid hormone)
link
Portfolio News
Jun 2, 2021
Bolt Biotherapeutics and Genmab Announce Oncology Research and Development Collaboration
link
Portfolio News
May 14, 2021
Apellis Announces FDA Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
link
Portfolio News
May 13, 2021
Vera Therapeutics Announces Pricing of Initial Public Offering
link
Portfolio News
May 4, 2021
Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
link
Portfolio News
Apr 29, 2021
Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency
link
Portfolio News
Apr 28, 2021
Pfizer Acquires Amplyx Pharmaceuticals
link
Portfolio News
Apr 28, 2021
Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer
link
Portfolio News
Apr 27, 2021
Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency
link
Event
Apr 23, 2021
Sarah Bhagat to join Investor Roundtable at the Virtual Neuroscience Innovation Forum (NIF) hosted by Sachs Associates on April 28 at 2:40pm ET
link
Portfolio News
Apr 20, 2021
Y-mAbs Provides Regulatory Update on Omburtamab
link
Portfolio News
Apr 19, 2021
Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial
link
Portfolio News
Apr 16, 2021
Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States
link
Portfolio News
Apr 13, 2021
Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss
link
Portfolio News
Apr 1, 2021
Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
link
Portfolio News
Mar 31, 2021
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing
link
Portfolio News
Mar 30, 2021
Amarin Receives European Commission (Ec) Approval for Vazkepa to Reduce Cardiovascular Risk
link
Portfolio News
Mar 30, 2021
VISEN’s TransConTM Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Schedule
link
Portfolio News
Mar 29, 2021
Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
link
Portfolio News
Mar 26, 2021
Gyroscope Therapeutics Announces $148 Million Raised in Series C Financing
link
Portfolio News
Mar 22, 2021
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
link
Portfolio News
Mar 18, 2021
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
link
Portfolio News
Mar 12, 2021
The Balancing Act® on Lifetime to Feature ENPP1 Deficiency
link
Sofinnova News
Feb 22, 2021
Jim Healy Receives 2021 NVCA “Excellence in Healthcare Innovation” Award for his Commitment to Improving the Lives of Patients Through Science
link
Portfolio News
Feb 17, 2021
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
link
Portfolio News
Feb 10, 2021
ObsEva Provides Business Outlook for 2021
link
Portfolio News
Feb 4, 2021
Bolt Biotherapeutics Prices Upsized Initial Public Offering
link
Portfolio News
Jan 21, 2021
Athira Pharma Announces Pricing of Public Offering of Common Stock
link
Portfolio News
Jan 19, 2021
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
link
Sofinnova News
Jan 12, 2021
Sofinnova’s Chief Legal Officer Hooman Shahlavi featured in Vanguard Law Magazine
link
Portfolio News
Jan 11, 2021
Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy
link
Portfolio News
Jan 9, 2021
VISEN Closes $150 Million Series B Financing to Accelerate the Development & Commercialization of its Innovative Endocrinology Therapies in Greater China
link
Portfolio News
Jan 8, 2021
Positive Phase 2b ICONA interim Results for Icosabutate in NASH Patients
link
Portfolio News
Jan 7, 2021
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
link
Portfolio News
Jan 4, 2021
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
link
Portfolio News
Dec 30, 2020
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
link
Sofinnova News
Dec 21, 2020
Sarah Bhagat featured in BioWorld: Gene Therapy Surges as Risks Reduced
link
Portfolio News
Dec 21, 2020
Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study
link
Portfolio News
Dec 18, 2020
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe
link
Portfolio News
Dec 18, 2020
Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China
link
Portfolio News
Dec 17, 2020
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
link
Portfolio News
Dec 16, 2020
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program
link
Portfolio News
Dec 10, 2020
ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
link
Portfolio News
Dec 8, 2020
Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study
link
Portfolio News
Dec 8, 2020
Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease
link
Sofinnova News
Dec 8, 2020
Sarah Bhagat Selected as One of Ten Winners for Biocom’s 2020 Life Science Catalyst Award
link
Portfolio News
Dec 8, 2020
Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab
link
Portfolio News
Dec 3, 2020
Natera Announced Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies
link
Event
Dec 1, 2020
Maha Katabi to join panel: “The Future of Biotech Financing: Continued Boom or Bust?” on December 3rd at 1pm ET
link
Portfolio News
Dec 1, 2020
Athira Pharma Announces Initiation of Patient Dosing for Treatment of Mild-to-Moderate Alzheimer’s Disease
link
Portfolio News
Nov 25, 2020
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
link
Portfolio News
Nov 23, 2020
Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research
link
Portfolio News
Nov 19, 2020
Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of Vascepa® (Icosapent Ethyl) in Mainland China
link
Portfolio News
Nov 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314
link
Portfolio News
Nov 18, 2020
Chiasma Announces Positive Topline Results from the MPOWERED™ Phase 3 Clinical Trial
link
Portfolio News
Nov 16, 2020
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
link
Portfolio News
Nov 16, 2020
Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
link
Portfolio News
Nov 5, 2020
Merck to Acquire VelosBio
link
Portfolio News
Oct 23, 2020
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe
link
Portfolio News
Oct 19, 2020
VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors
link
Portfolio News
Oct 7, 2020
Y-mAbs’ Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation & Rare Pediatric Disease Designation by FDA
link
Portfolio News
Oct 6, 2020
Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
link
Portfolio News
Sep 28, 2020
Sanofi Completes Principia Biopharma Inc. Acquisition
link
Portfolio News
Sep 17, 2020
Athira Pharma Announces Pricing of Initial Public Offering
link
Portfolio News
Sep 17, 2020
Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease
link
Portfolio News
Sep 16, 2020
Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19
link
Portfolio News
Sep 15, 2020
Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
link
Portfolio News
Sep 14, 2020
Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation
link
Portfolio News
Sep 8, 2020
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ hGH
link
Portfolio News
Aug 17, 2020
Sanofi to Acquire Principia Biopharma
link
Portfolio News
Aug 12, 2020
Ascendis Pharma Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe
link
Portfolio News
Aug 6, 2020
Aerovate Therapeutics Emerges With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy
link
Portfolio News
Jul 30, 2020
Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
link
Portfolio News
Jul 28, 2020
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration
link
Portfolio News
Jul 27, 2020
Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA®
link
Portfolio News
Jul 27, 2020
Checkmate Granted FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade
link
Portfolio News
Jul 27, 2020
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
link
Portfolio News
Jul 23, 2020
Inozyme Pharma Announces Pricing of Initial Public Offering
link
Portfolio News
Jul 21, 2020
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering
link
Portfolio News
Jul 20, 2020
Amplyx Announces Positive Top-Line Data in Phase 2 Clinical Trial Of Novel Antifungal Fosmanogepix
link
Portfolio News
Jul 20, 2020
Checkmate Pharmaceuticals Executes a Snappy 1-2 Biotech Gambit — Big Crossover Followed by an Instant IPO
link
Portfolio News
Jul 17, 2020
Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals
link
Portfolio News
Jul 16, 2020
Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
link
Portfolio News
Jul 14, 2020
Natera Recognized as a ‘Force for Change’ by Leading Women Entrepreneurs (LWE)
link
Portfolio News
Jul 8, 2020
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology
link
Portfolio News
Jul 7, 2020
NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors
link
Portfolio News
Jul 6, 2020
Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan
link
Portfolio News
Jul 6, 2020
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
link
Portfolio News
Jun 30, 2020
Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA
link
Portfolio News
Jun 29, 2020
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY
link
Portfolio News
Jun 26, 2020
Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog
link
Portfolio News
Jun 26, 2020
Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency
link
Portfolio News
Jun 25, 2020
Akouos Announces Pricing of Initial Public Offering
link
Portfolio News
Jun 23, 2020
Karuna Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia
link
Portfolio News
Jun 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
link
Portfolio News
Jun 15, 2020
Vascepa® Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified & Post Hoc Subgroup Analyses
link
Portfolio News
Jun 12, 2020
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
link
Portfolio News
Jun 10, 2020
Checkmate Pharmaceuticals Secures $85 Million in Series C Financing
link
Portfolio News
Jun 4, 2020
Athira Pharma Closes $85 Million Series B Financing
link
Portfolio News
May 14, 2020
Vascepa® Shows Significant Reduction in Coronary Revascularization in Prespecified Tertiary Endpoint Analyses
link
Portfolio News
May 14, 2020
Inozyme Pharma & GACI Global Initiate Patient Study to Improve Understanding of the Impact of Disease in Patients with ENPP1 Deficiency & ABCC6 Deficiency
link
Portfolio News
May 13, 2020
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
link
Portfolio News
May 13, 2020
Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease
link
Event
Apr 24, 2020
Maha Katabi to join Biotech by the Lake Investor Summit Panel: “Financing and Investing in Oncology Biotech”
link
Portfolio News
Apr 22, 2020
AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus
link
Portfolio News
Apr 22, 2020
Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
link
Portfolio News
Apr 19, 2020
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial
link
Portfolio News
Apr 16, 2020
Natera Prices $250 Million Convertible Senior Notes Due 2027
link
Portfolio News
Apr 15, 2020
Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering
link
Portfolio News
Apr 15, 2020
Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States
link
Portfolio News
Apr 1, 2020
Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA
link
Sofinnova News
Mar 31, 2020
Sofinnova Investments Strengthens Executive Team with the Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD
link
Sofinnova News
Mar 17, 2020
Sofinnova Investments Announces the Addition of Jonathan Leff, M.D. as Executive Partner
link
Portfolio News
Mar 3, 2020
Akouos Closes $105 Million Series B Financing
link
Portfolio News
Feb 26, 2020
Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab
link
Portfolio News
Feb 14, 2020
Promedior Announces Completion of Acquisition by Roche
link
Event
Feb 7, 2020
Maha Katabi to Present at the “Meet with Series” hosted by Johnson & Johnson Innovation, JLABS
link
Event
Feb 5, 2020
Jason Pitts to Moderate Bio CEO and & Investor Conference Panel: “Neuroscience at the Crossroads: Late Stage Brain Disorder Pipelines and Unmet Needs”
link
Event
Jan 20, 2020
Jim Healy to join SuperReturn 2020 Panel: “Keeping Things Private or Going Public – Considering the Exit”
link
Portfolio News
Jan 15, 2020
Astellas Completes Acquisition of Audentes Therapeutics
link
Portfolio News
Jan 13, 2020
Chiasma Announces FDA Acceptance Of MYCAPSSA® New Drug Application Resubmission
link
Portfolio News
Jan 8, 2020
NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH
link
Event
Dec 17, 2019
Maha Katabi to join Biotech Showcase 2020 Panel “Rare and Orphan Diseases: The Value Proposition of New Modalities vs Established Ones”
link
Portfolio News
Dec 2, 2019
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutic
link
Portfolio News
Nov 20, 2019
Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
link
Portfolio News
Nov 18, 2019
Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
link
Portfolio News
Nov 18, 2019
Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche
link
Portfolio News
Oct 25, 2019
Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product
link
Portfolio News
Oct 21, 2019
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe
link
Portfolio News
Oct 3, 2019
Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases
link
Event
Oct 1, 2019
Jim Healy to join BIO Investor Forum Panel “Market Outlook—Taking the Temperature of the IPO Market in an Era of Large Pharma M&A”
link
Portfolio News
Sep 26, 2019
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
link
Portfolio News
Sep 23, 2019
Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back
link
Portfolio News
Sep 12, 2019
Akouos Discloses Lead Program, AK-OTOF, a Potential Gene Therapy for Sensorineural Hearing Loss
link
Portfolio News
Sep 9, 2019
Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period
link
Portfolio News
Aug 7, 2019
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
link
Portfolio News
Aug 5, 2019
Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema
link
Portfolio News
Aug 5, 2019
Natera Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies
link
Portfolio News
Jul 23, 2019
Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa®
link
Portfolio News
Jul 15, 2019
Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria
link
Portfolio News
Jul 8, 2019
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1
link
Portfolio News
Jun 27, 2019
Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering
link
Sofinnova News
May 31, 2019
Swinging for the Fences: The Dichotomy in Rare Disease Investment and Development
link
Portfolio News
May 14, 2019
CinCor Pharma Closes $50 Million Series A
link
Sofinnova News
Apr 22, 2019
Sofinnova Investments Announces the Addition of Industry Veteran Maha Katabi, PhD. as a Partner
link
Portfolio News
Apr 10, 2019
Inozyme Pharma Raises $67 Million in Series A2 Financing
link
Portfolio News
Mar 28, 2019
Amarin shares new updates to the American Diabetes Association 2019 Standards of Medical Care in Diabetes
link
Portfolio News
Mar 19, 2019
Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation
link
Portfolio News
Mar 4, 2019
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint
link
Portfolio News
Feb 25, 2019
Spark Therapeutics Enters into Definitive Merger Agreement with Roche
link
Event
Feb 4, 2019
Jim Healy to join Bio CEO & Investor Panel “Are Record Levels of IPOs Still Disrupting M&A Deals?”
link
Portfolio News
Jan 31, 2019
Kiniksa Pharmaceuticals Announces Pricing of Public Offering
link
Sofinnova News
Jan 25, 2019
A Top VC At a $2B Fund That Invests in Risky Biotechs Reveals How He Finds His Best Investments
link
Event
Dec 13, 2018
Mike Powell joins AACR Panel “Entrepreneurship in Translational Research”
link
Event
Dec 12, 2018
Jim Healy to join East | West CEO Panel “VC Perspectives: Currant Financing Trends in Biotech”
link
Event
Dec 12, 2018
Jim Healy to join Biotech Showcase Panel “Rare and Orphan Diseases”
link
Portfolio News
Dec 6, 2018
XyloCor Therapeutics Raises $17 Million in Series A
link
Portfolio News
Nov 27, 2018
BioClin Therapeutics Announces Name Change to Rainier Therapeutics
link
Portfolio News
Nov 13, 2018
NextCure Completes a $93M Series B Financing
link
Portfolio News
Nov 7, 2018
InCarda Completes $42M Oversubscribed Series B Financing
link
Portfolio News
Nov 5, 2018
NextCure and Lilly Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines
link
Portfolio News
Nov 2, 2018
U.S. FDA Approves Coherus Biosciences’ UDENYCA™
link
Sofinnova News
Oct 29, 2018
Sarah Bhagat Named as One of the “Nine VCs Who Matter, but You Never Read About”
link
Sofinnova News
Oct 16, 2018
Mike Powell and Jason Pitts Featured in EndPoints Guest Column “The Real Cost of Drug Development”
link
Portfolio News
Oct 3, 2018
ObsEva Reports Additional Positive Phase 3 Results IMPLANT 2 Trial Following IVF
link
Portfolio News
Sep 28, 2018
ObsEva’s Final Results of Phase 2b EDELWEISS Trial Shows Sustained Efficacy and Safety
link
Portfolio News
Sep 26, 2018
Entasis Therapeutics Announces Pricing of Initial Public Offering
link
Portfolio News
Sep 25, 2018
Coherus Biosciences Receives European Commission Approval for Udenyca™
link
Portfolio News
Sep 24, 2018
Amarin’s REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® Capsules Met Primary Endpoint
link
Portfolio News
Sep 20, 2018
Y-mAbs Therapeutics Announces Pricing of Initial Public Offering
link
Portfolio News
Sep 19, 2018
Galera Therapeutics Raises $150M
link
Portfolio News
Sep 18, 2018
BioClin Therapeutics Announces New Leadership
link
Portfolio News
Sep 13, 2018
Principia Biopharma Announces Pricing of Initial Public Offering
link
Portfolio News
Aug 16, 2018
A women’s health startup tried to drum up interest for a much-needed drug. Many men didn’t get it.
link
Portfolio News
Aug 7, 2018
Akouos Raises $50M Series A Financing
link
Portfolio News
May 24, 2018
Iterum Announces the Pricing of Initial Public Offering
link
Portfolio News
May 23, 2018
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering
link
Portfolio News
May 14, 2018
Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282
link
Portfolio News
May 7, 2018
BioClin Therapeutics, Inc., Completes $50M Series B Financing with Addition of New Investors
link
Portfolio News
Mar 28, 2018
Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study
link
Event
Jan 30, 2018
Alan Colowick to Speak at JLABS
link
Portfolio News
Jan 22, 2018
Medeor Therapeutics Awarded $18.8M From the California Institute for Regenerative Medicine
link
Portfolio News
Jan 4, 2018
Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO
link
Portfolio News
Jan 3, 2018
Ascendis Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone
link
Portfolio News
Dec 19, 2017
Spark Therapeutics Announces FDA approval of LUXTURNA™
link
Portfolio News
Dec 18, 2017
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa®
link
Portfolio News
Dec 15, 2017
Aclaris Therapeutics Receives FDA Approval for the Treatment of Raised Seborrheic Keratoses
link
Portfolio News
Dec 13, 2017
Pionyr Immunotherapeutics Completes $62M Series B Financing
link
Portfolio News
Nov 29, 2017
Y-mAbs Announces Closing of $30M Extension of Private Equity Placement
link
Portfolio News
Nov 28, 2017
Medeor Therapeutics Raises $57M In Series B Financing
link
Portfolio News
Nov 14, 2017
Apellis Announces the Pricing of Initial Public Offering
link
Portfolio News
Nov 7, 2017
ObsEva Announces Completion of Patient Recruitment for the Treatment of Endometriosis
link
Sofinnova News
Oct 24, 2017
Sofinnova Steps Up
link
Portfolio News
Sep 27, 2017
NuCana PLC Announces Pricing of Initial Public Offering
link
Portfolio News
Sep 5, 2017
Entasis Announces $31.9M Extension of Series B Financing
link
Portfolio News
Aug 10, 2017
Apellis Pharmaceuticals Announces $60M Series E Financing
link
Portfolio News
Aug 2, 2017
Amplyx Pharmaceuticals Raises $67M in Series C Financing
link
Portfolio News
Jun 15, 2017
Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals
link
Event
Jun 9, 2017
Jim Healy to Speak at BIO on Market & Political Pressures
link
Event
Jun 7, 2017
Mike Powell to be a Judge at BIO’s Start-Up Stadium
link
Sofinnova News
May 30, 2017
Sofinnova Announces the Addition of Industry Leader Alan Colowick, MD, MPH to its Partnership
link
Event
Apr 11, 2017
Jim Healy to Speak at Cancer Advance Boston
link
Portfolio News
Mar 28, 2017
Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy
link
Event
Feb 6, 2017
Charlotte Shropshire to Speak at SuperReturn US West
link
Sofinnova News
Oct 17, 2016
Sofinnova Raises $650M Biotech-focused Venture Fund
link
Sofinnova News
Apr 11, 2016
12 VCs Who Matter, But You Never Read About
link
Sofinnova News
Jan 12, 2016
Despite ‘choppy’ markets, fundamentals strong as health care world heads to JPM
link
Portfolio News
Dec 4, 0202
Atsena Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101
link